{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:03:20Z","timestamp":1769601800898,"version":"3.49.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0147381","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T18:51:03Z","timestamp":1457031063000},"page":"e0147381","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics"],"prefix":"10.1371","volume":"11","author":[{"given":"Ella","family":"Willenbacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Weger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Rochau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Austrian Myeloma Registry (AMR)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"SK Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study","volume":"26","author":"SK Kumar","year":"2012","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"J San Miguel","year":"2013","journal-title":"The Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"EM Ocio","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"DS Siegel","year":"2012","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","article-title":"A Primer on Effectiveness and Efficacy Trials","volume":"5","author":"A Singal","year":"2014","journal-title":"Clinical and Translational Gastroenterology"},{"key":"ref7","unstructured":"FDA website. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fdanews.com\/CTA0617151?hittrk=CTA1561&utm_source=Real%20Magnet&utm_medium=Email&utm_campaign=76759603\" xlink:type=\"simple\">http:\/\/www.fdanews.com\/CTA0617151?hittrk=CTA1561&amp;utm_source=Real%20Magnet&amp;utm_medium=Email&amp;utm_campaign=76759603<\/ext-link>"},{"key":"ref8","unstructured":"Coordinating ethical review board: Ethic commission of the Medical University of Innsbruck Innrain 43, A-6020 Innsbruck, Austria. Decision: vote 3252, session266\/ 4.2, passed JUL 10, 2008"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"SV Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"282","key":"ref10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"EL Kaplan","year":"1958","journal-title":"J. Amer. Statist. Assn"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"WJ Chng","year":"2014","journal-title":"Leukemia"},{"key":"ref12","article-title":"Modelling Survival Data in Medical Research","author":"D Collett","year":"1997"},{"key":"ref13","article-title":"Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study","author":"M Mohty","year":"2015","journal-title":"IMW"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Mohty M, Terpos E, Mateos MV, Palumbo A, Lejniece S, et al. Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice). Accepted for ASH 2015 (# 3034)","DOI":"10.1182\/blood.V126.23.3034.3034"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ajh.23753","article-title":"Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents","volume":"89","author":"MA Al-Hamadi","year":"2014","journal-title":"American Journal of Hematology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"B Barlogie","year":"2014","journal-title":"Blood"},{"key":"ref17","first-page":"7","article-title":"for the Myeloma Platform of the Austrian Society of Hematology and Oncology (\u00d6GHO)","volume":"3","author":"E Gunsilius","year":"2010","journal-title":"memo"},{"key":"ref18","article-title":"Continued Overall Survival Benefit After 5 Years&apos; Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial","volume":"118","author":"JF San Miguel","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in Multiple Myeloma according to patient age and vulnerability: a report from the European Myeloma Network (EMN)","volume":"118","author":"A Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref20","article-title":"Carfilzomib, lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","author":"AK Stewart","year":"2014","journal-title":"NEJM"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0147381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T15:40:29Z","timestamp":1600270829000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0147381"}},"subtitle":[],"editor":[{"given":"Ken","family":"Mills","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0147381","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}